All
FDA Sets Date for Full Approval, Broader Indication for Elevidys
February 16th 2024The FDA has set a PDUFA date of June 21, 2024, to convert the accelerated approval to full approval and expand the labeling of the gene therapy Elevidys beyond the current use in children aged 4 and 5 with Duchenne muscular dystrophy.